{
  "source": "PA-Notification-Qfitlia.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1480-1\nProgram Prior Authorization/Notification\nMedication Qfitlia® (fitusiran)\nP&T Approval Date 5/2025\nEffective Date 7/1/2025\n1. Background:\nQfitlia (fitusiran) is an antithrombin-directed small interfering ribonucleic acid indicated for\nroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric\npatients aged 12 years and older with hemophilia A or B with or without factor VIII or IX\ninhibitors.\n2. Coverage Criteriaa:\nA. Hemophilia A\n1. Initial Authorization\na. Qfitlia will be approved based on both of the following criteria\n(1) Diagnosis of hemophilia A\n-AND-\n(2) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Qfitlia therapy\nAuthorization will be issued for 12 months.\nB. Hemophilia B\n1. Initial Authorization\na. Qfitlia will be approved based on both of the following criteria\n(1) Diagnosis of hemophilia B\n-AND-\n(2) Prescribed for the prevention of bleeding episodes (i.e., routine prophylaxis)\n© 2025 UnitedHealthcare Services Inc.\n1\nAuthorization of therapy will be issued for 12 months.\n2. Reauthorization\na. Documentation of positive clinical response to Qfitlia therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Medical Necessity may be in place\n4. References:\n1. Qfitlia® [package ",
    "es (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Medical Necessity may be in place\n4. References:\n1. Qfitlia® [package insert]. Cambridge, MA: Genzyme Corporation; March 2025.\nProgram Prior Authorization/Notification - Qfitlia (fitusiran)\nChange Control\n5/2025 New program\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}